Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Names New Member to Its Board of Directors
05:00pm, Tuesday, 28'th Sep 2021
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Names New Member to Its Board of Directors
Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate
01:54pm, Tuesday, 28'th Sep 2021
Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
09:23am, Monday, 27'th Sep 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
11:08am, Thursday, 23'rd Sep 2021
Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America. Related: Incyte's Pemazyre Wi
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD
10:42am, Thursday, 23'rd Sep 2021
Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
07:30am, Thursday, 23'rd Sep 2021
MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a de
Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD
01:54pm, Wednesday, 22'nd Sep 2021
The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for adult and pediatric patients 12 years and
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
12:38pm, Wednesday, 22'nd Sep 2021
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for treatment of chronic graft-versus-host
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
11:36am, Wednesday, 22'nd Sep 2021
Find out what held these laggards back.
Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis
09:57am, Wednesday, 22'nd Sep 2021
Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
07:05am, Wednesday, 22'nd Sep 2021
The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD). Also Read:
Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada
01:46pm, Monday, 20'th Sep 2021
Health Canada has given conditional approval to Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma. Cholangiocarcinoma is a type of cancer that forms in the sle
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV--Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
Insider Buying at These Biotech Firms Indicates Value
11:18am, Friday, 03'rd Sep 2021
According to Wall Street legend, a young person approached one of the top businessmen in the U.S. (said to be J.P. Morgan, the founder of his namesake bank J.P.
Should You Buy Incyte Stock Around $75 Levels?
10:00am, Wednesday, 01'st Sep 2021
We believe that the stock price of Incyte, a global biopharmaceutical company, is undervalued at current levels of $75. INCY stock is down 21% over the last-twelve months period, despite revenue incre
